Acorda Therapeutics, Inc. (ACOR.O)
25.06USD
18 Dec 2009
$0.77 (+3.17%)
$24.29
$24.50
$25.09
$24.40
904,442
313,242
$29.27
$15.52
ACOR.O
About
Overall
| Beta: | 0.84 |
| Market Cap (Mil.): | $925.94 |
| Shares Outstanding (Mil.): | 38.12 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| ACOR.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.78 | 4.61 |
| EPS (TTM): | -1.50 | -- | -- |
| ROI: | -31.29 | 1.35 | 2.83 |
| ROE: | -42.93 | 2.17 | 3.59 |
Enzyme eats scar tissue that blocks spine repair
CHICAGO, Nov 2 (Reuters) - U.S. researchers have engineered an enzyme that can gobble up scar tissue formed after spinal cord injuries, overcoming a key hurdle to getting injured nerves to reconnect and heal.
Oracle hedge fund chief sees healthcare sector boom
NEW YORK, Nov 1 (Reuters) - U.S. healthcare reform is likely to benefit hospital, drug and biopharmaceutical companies if it becomes reality this year or next, Barron's business weekly said on Sunday.
UPDATE 1-FDA extends review date of Acorda's MS drug by 3 months
Oct 22 (Reuters) - Acorda Therapeutics Inc said U.S. regulators extended the review date for its experimental multiple sclerosis treatment by three months after the company submitted additional data related to the drug.
Swiss stocks - Factors to watch on Oct 16
ZURICH, Oct 16 (Reuters) - Swiss shares were poised to open stronger on Friday, as earnings reports continued to point to a recovering economy, boosting markets in Asia and America.
Acorda shares soar after FDA panel backs MS drug
NEW YORK (Reuters) - Acorda Therapeutics Inc shares soared nearly 50 percent on Thursday as analysts said a U.S. Food and Drug Administration panel review of the company's multiple sclerosis drug paved the way for approval by next year.
UPDATE 2-Acorda shares soar after FDA panel backs MS drug
* Shares jump 49.8 percent (Adds Acorda declining to comment on takeover speculation in last paragraph; updates shares)
UPDATE 2-U.S. advisers back Acorda walking drug for MS
* Approval decision expected by Oct. 22 (Recasts first paragraph with panel backing; adds testimony to panel, background on drug, byline)
HEADLINE STOCKS-Some U.S. stocks on the move on Oct. 9
NEW YORK, Oct 9 (Reuters) - Some U.S. stocks on the move on Friday:
UPDATE 2-Acorda shares fall over FDA concerns for MS drug
* Shares fall more than 18 percent (Adds share price, company comment, background on drug)
HEADLINE STOCKS-Some U.S. stocks on the move on Oct. 9
(Updates to after the open, adds Citigroup/Occidental, AK Steel, Sunrise, Acorda, MDS, Kimberly Clark/I-Flow, Scientific Learning)
Competitors
| Price | Change | |
|---|---|---|
| Biogen Idec Inc. (BIIB.OQ) | $50.07 | +0.62 |
| Schering-Plough Corporation (SGP.N) | -- | -- |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | ₪20,120.00 | -80.00 |
| Merck & Co., Inc. (MRK.N) | $37.40 | +0.12 |
| Elan Corporation, plc (ELN.I) | €4.60 | +0.08 |
| Sanofi-Aventis SA (SASY.PA) | €54.70 | +1.26 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
